Compare PRCH & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | MPLT |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2019 | 2025 |
| Metric | PRCH | MPLT |
|---|---|---|
| Price | $17.06 | $11.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $18.63 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | 82.39 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $482,414,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $17.05 | N/A |
| P/E Ratio | $1,709.00 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $6.36 | $9.10 |
| 52 Week High | $19.44 | $40.43 |
| Indicator | PRCH | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 65.65 | 30.32 |
| Support Level | $9.08 | $10.83 |
| Resistance Level | N/A | $20.20 |
| Average True Range (ATR) | 0.73 | 0.96 |
| MACD | 0.05 | 0.59 |
| Stochastic Oscillator | 83.97 | 25.08 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.